247 related articles for article (PubMed ID: 27669062)
1. Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
Lamote K; Vynck M; Van Cleemput J; Thas O; Nackaerts K; van Meerbeeck JP
J Breath Res; 2016 Sep; 10(4):046001. PubMed ID: 27669062
[TBL] [Abstract][Full Text] [Related]
2. Exhaled breath to screen for malignant pleural mesothelioma: a validation study.
Lamote K; Vynck M; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Eur Respir J; 2017 Dec; 50(6):. PubMed ID: 29269578
[TBL] [Abstract][Full Text] [Related]
3. Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
Töreyin ZN; Ghosh M; Göksel Ö; Göksel T; Godderis L
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32050546
[TBL] [Abstract][Full Text] [Related]
4. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
Dragonieri S; van der Schee MP; Massaro T; Schiavulli N; Brinkman P; Pinca A; Carratú P; Spanevello A; Resta O; Musti M; Sterk PJ
Lung Cancer; 2012 Mar; 75(3):326-31. PubMed ID: 21924516
[TBL] [Abstract][Full Text] [Related]
5. Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.
Lamote K; Brinkman P; Vandermeersch L; Vynck M; Sterk PJ; Van Langenhove H; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Oncotarget; 2017 Oct; 8(53):91593-91602. PubMed ID: 29207669
[TBL] [Abstract][Full Text] [Related]
6. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
8. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study.
Westhoff M; Litterst P; Freitag L; Urfer W; Bader S; Baumbach JI
Thorax; 2009 Sep; 64(9):744-8. PubMed ID: 19158121
[TBL] [Abstract][Full Text] [Related]
9. Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results.
Zwijsen K; Schillebeeckx E; Janssens E; Cleemput JV; Richart T; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
J Breath Res; 2023 Sep; 17(4):. PubMed ID: 37683624
[TBL] [Abstract][Full Text] [Related]
10. Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
Di Gilio A; Catino A; Lombardi A; Palmisani J; Facchini L; Mongelli T; Varesano N; Bellotti R; Galetta D; de Gennaro G; Tangaro S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429446
[TBL] [Abstract][Full Text] [Related]
11. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
12. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
13. Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.
Gopar-Nieto R; Aguilar-Madrid G; Sotelo-Martínez L; Juárez-Pérez CA; Kelly-García J; Argote-Greene L; Ochoa-Vázquez MD; García-Bazán EM; Ramírez-Pérez J; Haro-García L; Jiménez-Ramírez C; Cabello-López A
Arch Med Res; 2015 Feb; 46(2):107-11. PubMed ID: 25707292
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
15. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
16. Non-asbestos-related malignant pleural mesothelioma.
Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
[TBL] [Abstract][Full Text] [Related]
17. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort.
Allione A; Viberti C; Cotellessa I; Catalano C; Casalone E; Cugliari G; Russo A; Guarrera S; Mirabelli D; Sacerdote C; Gentile M; Eichelmann F; Schulze MB; Harlid S; Eriksen AK; Tjønneland A; Andersson M; Dollé MET; Van Puyvelde H; Weiderpass E; Rodriguez-Barranco M; Agudo A; Heath AK; Chirlaque MD; Truong T; Dragic D; Severi G; Sieri S; Sandanger TM; Ardanaz E; Vineis P; Matullo G
Int J Cancer; 2023 Feb; 152(4):725-737. PubMed ID: 36305648
[TBL] [Abstract][Full Text] [Related]
18. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
Watzka SB; Posch F; Pass HI; Flores RM; Hannigan GE; Bernhard D; Weber M; Mueller MR
Eur J Cardiothorac Surg; 2013 May; 43(5):940-5. PubMed ID: 23045294
[TBL] [Abstract][Full Text] [Related]
19. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
20. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
